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Abstract
The growth of a malignant tumor beyond a certain, limited size requires that it first develop an independent blood supply.
In addition to providing metabolic support, this neovasculature also allows tumor cells to access the systemic circulation,
thus facilitating metastatic dissemination. The neovasculature may originate either from normal blood vessels in close
physical proximity to the tumor and/or from the recruitment of bone marrow-derived endothelial cell (EC) precursors.
Recent studies have shown that human tumor vasculature ECs may also arise directly from tumor cells themselves and that
the two populations have highly similar or identical karyotypes. We now show that, during the course of serial in vivo
passage, these tumor-derived ECs (TDECs) progressively acquire more pronounced EC-like properties. These include higher-
level expression of EC-specific genes and proteins, a greater capacity for EC-like behavior in vitro, and a markedly enhanced
propensity to incorporate into the tumor vasculature. In addition, both vessel density and size are significantly increased in
neoplasms derived from mixtures of tumor cells and serially passaged TDECs. A comparison of early- and late-passage
TDECs using whole-genome single nucleotide polymorphism profiling showed the latter cells to have apparently evolved by
a process of clonal expansion of a population with a distinct pattern of interstitial chromosomal gains and losses affecting a
relatively small number of genes. The majority of these have established roles in vascular development, tumor suppression
or epithelial-mesenchymal transition. These studies provide direct evidence that TDECs have a strong evolutionary capacity
as a result of their inherent genomic instability. Consequently such cells might be capable of escaping anti-angiogenic
cancer therapies by generating resistant populations.
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Introduction
The growth of a tumor beyond a certain small size is highly
dependent upon the development of an independent vasculature
[1–4]. This ‘‘angiogenic switch’’, which may not be activated until
years after the initial neoplasm has developed [5,6], has until
recently generally been viewed as having two origins. The first,
termed ‘‘sprouting’’ angiogenesis, or simply angiogenesis, is a
consequence of the re-directing of pre-existing neighboring blood
vessels into the tumor bed, whereas the second, termed
vasculogenesis, stems from the recruitment of bone marrow-
derived endothelial cell (EC) precursors [7,8]. Both processes may
operate independently and concurrently and are regulated by
specific inductive signals originating from the tumor and/or its
associated inflammatory cell infiltrate [8,9]. Once developed, the
neo-vasculature becomes the tumor’s main source of oxygen and
nutrients, whose delivery is no longer diffusion-dependent. It also
serves as a major portal for tumor cell invasion of the systemic
circulation, thus abetting metastasis [3,6].
Given the neovasculature’s importance in supporting many of
the tumor’s most critical metabolic needs and functions, much
effort has been devoted to the design of anti-angiogenesis therapies
[10,11]. One attraction of this approach is that the cells
comprising the vasculature are presumed to be genomically stable
and thus less predisposed to the development of the therapy
resistance commonly encountered in tumor cells [2,3]. Despite this
major theoretical advantage, clinical trials with these approaches
have extended patient survival only modestly and the eventual
development of resistance is actually quite common, although its
cause remains largely unexplored [12–15].
We and others have described a third origin for the EC
population of several tumor types in the form of ‘‘tumor-derived
ECs’’ (TDECs) [16–18], which arise stochastically from tumor
epitlelium. TDECs express EC-specific markers, contain Weibel-
Palade bodies, form tube-like structures in semi-solid media, and
incorporate into functional tumor vasculature. These properties
distinguish TDECs from tumor cells undergoing vasculogenic
mimicry, a reversible process involving a partial epithelial-
mesenchymal transition (EMT) [19,20]. As expected for actual
tumor cell descendants, TDEC karyotypes are distinctly abnormal
and contain tumor-specific chromosomal markers. These findings
suggest that, like their ancestral tumor cells, TDECs might possess
inherent genomic instability (GI) and thus be prone to develop
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this idea, we show here that upon continued in vivo serial passage,
the TDEC population acquires a more pronounced EC-like
phenotype. Whole genome single nucleotide polymorphism (SNP)
array analysis indicates that serially-passaged TDECs also acquire
a small number of genomic amplifications and deletions. The
known genes contained within these affected regions are dispro-
portionately involved in functions pertaining to tumor suppression,
vasculogenesis, and EMT. These findings support the idea that the
long-term propagation of TDECs leads to the emergence of a
more functionally robust clonal population that is facilitated by
underlying GI.
Results
TDEC Recovery Increases with Serial Passage
The H460 human lung cancer cell line was originally tagged
with lentiviral vectors separately encoding green fluorescent
protein (GFP) and resistance to G418 [16]. Tumor xenografts
from these cells were initially grown in immuno-compromised
nude mice and the total human and murine EC populations were
isolated with anti-CD31-coupled magnetic beads as previously
described [16]. Approximately 40% of the total ‘‘tumor-associated
ECs’’ (TAECs) expressed GFP, were G418-resistant and contained
only human chromosomes, thus indicating that they were true
TDECs [16]. These ‘‘serial passage 0’’ (SP0) TDECs were then
mixed with a 20-fold excess of untagged H460 cells and re-
propagated with tumor xenografts. Upon reaching maximal
allowable size, each tumor was excised and its its total TAEC
population, now referred to as SP1, was again isolated. The GFP+
TDECs, which comprised approximately 5% of the entire TAEC
population, were then purified and expanded for several days in
G418-containing medium, combined again with a 20-fold excess
of untagged H460 tumor cells and propagated as tumor
xenografts. Several such serial in vivo passages were performed
with the percent of retrieved GFP+ TDECs in the total TAEC
population being determined periodically. While the earliest
passage TDECs (SP1 and SP2) consistently yielded about 5%
GFP+ TDEC recovery, later passages (SP4–SP6) provided for
recovery rates in excess of 30% (Figure 1A). This was consistent
with the observation that these later passage TDECs were more
frequently associated with tumor blood vessel endothelium
(Figure 1B).
To establish further that the late passage cells could out-
compete their early passage counterparts, we derived SP0
TDECs from an H460 tumor tagged with a red fluorescent
protein (dsRed) rather than GFP. The SP0 (dsRed+) TDECs
and SP6 (GFP+) TDECs were then mixed in equal numbers,
combined with untagged H460 cells at a 1:20 ratio as before,
and grown as tumor xenografts. Just prior to total TAEC
harvesting, fluorescence imaging of the mouse was performed
using a Xenogen IVIS-200 in vivo imaging system. As seen in
Figure 1C, the dsRed signal localized to discrete regions, that
recapitulated the distribution previously seen for tumors
containing early passage TDECs [16], while the GFP signal
was more evenly distributed throughout the tumor. Following
the isolation of TAECs, the red and green TDEC populations
were quantified by direct UV microscopy. In three independent
tumor xenografts, there was an average of .6-fold greater
abundance of GFP+ TDECs than of dsRed+ TDECs
(Figure 1D). Taken together, these observations indicate that
late passage TDECs outcompete early passage TDECs, even
when the two populations co-exist under identical in vivo
conditions.
Late Passage TDECs Express Higher Levels of some EC-
specific Markers
We previously reported that early passage H460-derived
TDECs, as well as those originating from several other tumor
cell types, stably express numerous EC-specific markers [16].
Having demonstrated that late passage TDECs outcompete early
passage TDECs and incorporate into the tumor vasculature more
efficiently, we next asked whether they do so in association with
higher level expression of these markers. Thus, we used flow
cytometry to follow the cell surface expression of CD31 on TDECs
during the course of serial in vivo passage and observed that it
increased by nearly 30-fold (Fig. 2A). This increase was confirmed
by immunoblotting (Fig. 2C). Similarly, several other EC-specific
markers, including uptake of acetylated LDL (AcLDL), expression
of E-lectin receptor, von Willebrand’s factor (vWF) and EC-
selective adhesion molecule (ESAM), also increased over the
course of serial passage, rivaling the levels observed in human
umbilical vein endothelial cells (HUVECs) and coinciding with the
acquisition of a more EC-like morphology (Fig. 2B). Finally, an
examination of EC-specific transcripts, which had previously
shown 2 to100-fold increases in SP0 TDECs relative to parental
H460 tumor cells [16], showed additional 1.6 to 5.1-fold increases
in expression between SP1 and SP7 TDECs (Figure 2D). Taken
together, these studies demonstrate further up-regulation of
numerous EC specific markers during the course of TDEC serial
passage.
Late Passage TDECs form more Complete Tube-like
Structures and Become Hypoxia-responsive
One hallmark of ECs is their ability to form 3-dimensional tube-
like structures resembling capillaries in semisolid media [21,22].
When cultured under standard normoxic conditions for six days in
Matrigel, H460 tumor cells formed only acini, while both early
and late passage H460-derived TDECs generated abortive,
network-like structures only partially resembling those formed by
HUVECs (Figure 3A and reference 16). In contrast, when TDECs
were cultured for 6 days under moderately hypoxic conditions (1%
O2) followed by a 4 day normoxic recovery period, a more
complete HUVEC-like tube pattern was observed with late, but
not early, passage TDECs (Figure 3B and C). TDEC serial passage
thus is associated with an enhanced tube-forming ability, which
requires hypoxic stress for optimal expression.
ToexplorefurthertheinvitroEC-likepropertiesofTDECs,weco-
culturedHUVECswithGFP-taggedH460cellsorwithearlyorlate
passage H460-derived GFP+ TDECs. We reasoned that, during
propagationinMatrigel,HUVECsmightprovidesupportivefactors
thatwouldenhancetheabilityofTDECstoformtube-likestructures.
After2 dofisolatedculture,H460andearlyandlatepassageTDECs
culturedaloneremainedpredominantlysingle,roundedcellsandhad
not formed tubes (Figure S1). However, when co-cultured with
HUVECs,weobservedagreatertendencyoflatepassageTDECsto
elongateandincorporateinto(notjustassociatewith)HUVECtubes
comparedto eitherearly passageTDECsorH460cells(Figure3D).
These results are consistent with those shown in Figure 3A–C and
indicate that late passage TDECs are more responsive to and
cooperate better with neighboring HUVECs than early passage
TDECs.
Enhanced Vascularization Potential of Serially-passaged
TDECs
We next examined whether the tumors arising from H460
tumor cells containing a 5% contribution of late-passage TDECs
might be more highly vascularized than those arising from a
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tumor cells (control tumors). Paraffin-embedded sections of tumor
xenografts were stained with hematoxylin and eosin to identify
tumor blood vessels. We found that tumors originating from the
inocula containing late-passage TDECs tended to be supplied by
blood vessels that were both denser and larger than those seen in
the other two tumor groups (Figure 4A–C). Thus, continued serial
passage of TDECs is associated with an enhanced ability to
establish a functional tumor vasculature.
Late Passage TDECs have Defined Genomic Gains/
deletions that Affect Gene Expression
As late passage TDECs have more pronounced EC-like
phenotypes than their early passage counterparts, it seemed
possible that serial propagation might be selecting for a
subpopulation of cells inherently better at contributing to tumor
blood vessel formation. This process could be accelerated if
TDECs, like the tumor cells from which they originate, were more
genomically unstable than host-derived ECs. To test this
hypothesis, we compared genome-wide SNP profiles of H460
cells and early and late passage TDECs. No differences were
observed in the SNP profiles of early-passage TDECs (SP0 and
SP1) and H460 cells, whereas late-passage TDECs (SP5 and SP6)
showed identical genomic alterations (Figures S2, S3, S4, S5, S6,
and S7). Aside from the loss of one copy of chromosome 14, these
consisted of a relatively small number of deletions and gains (8 and
2, respectively) ranging in size from approximately 56 kb to
435 kb (Figure 5, Table 1, and Figures S2, S3, S4, S5, S6, S7).
Seven of the ten genomic gains/deletions in late-passage TDECs
were found to be intragenic (Table 1), whereas nine additional
genes were located within the immediate vicinity of the affected
loci (Table 1). Interestingly, five of the genes with intragenic
alterations and 6 of the adjacent genes have been previously linked
to tumorigenesis, vasculogenesis or the EMT and several have also
Figure 1. Increased tumor re-populating ability of serially-passaged TDECs. (A) Human and murine TAECs were isolated from initial H460
lung cancer xenografts by CD31 immuno-affinity purification [16]. The latter were then eliminated by propagating the cells in G-418 and the resultant
GFP+, G418-resistant human TDECs were then serially passaged in vivo with a 20-fold excess of non-GFP-tagged H460 tumor cells. At the indicated
passage numbers, the percent of GFP+ TDECs was determined 1–2 days after isolation and before the addition of G-418. The results shown represent
the average values obtained from 3–5 fields (6SEM) with a total of 738, 761, 128, and 296 cells counted for SP1, SP2, SP4, and SP6, respectively. The
statistical analysis was performed using a two-tailed Student’s t test (**, p,0.01; ***, p,0.0001). (B) Photomicrographs of typical blood vessels from
H460 tumor xenografts established as described in A for serial passages SP1 and SP5. Frozen sections were visualized for GFP and stained for human-
specific CD31 (hCD31) (red) and DAPI (blue). Images were taken at 206 magnification. (C) Live animal imaging of tumor xenografts arising in a
representative mouse co-inoculated with an equal number of dsRed-tagged SP0 TDECs and GFP-tagged SP6 TDECs plus a 20-fold excess of untagged
H460 tumor cells. (D) Quantification of the percent red SP1 versus the percent green SP7 TDECs isolated from three tumors. The graph represents the
mean values (6SEM) with the p value determined using a one-tailed Student’s t test.
doi:10.1371/journal.pone.0037138.g001
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Taken together, these results indicate that late passage TDECs
appear to arise through a process of clonal selection and possess
discrete regions of genomic gain/deletion commonly involving
genes with functions potentially relevant to the transition from
tumor epithelium to ECs.
OurSNPfindingssuggestedthattheexpressionofgenescontained
within or adjacent to the amplified/deleted regions of late passage
Figure 2. EC-specific marker expression increases in serially-passaged H460-derived TDECs. (A) Cell surface staining for hCD31.
TDECs from the indicated serial passages were isolated and the cell surface expression of the EC-specific marker hCD31 was then assessed by
flow cytometry. (B) AcLDL uptake, E-lectin binding and anti-human vWF (hvWF) and anti-human ESAM (hESAM) immuno-staining were assessed
in early and late TDECs using confocal microscopy (16). HUVECs were included as positive controls. Nuclei were stained with DAPI (blue). H&E
staining under light microscopy was used to compare the morphologies of H460 tumor cells, TDECs, and HUVECs. Images were obtained at
202406 magnification. (C) Expression of CD31 and vWF assessed by immuno-blotting. Early- and late-passage TDECs were examined by
immuno-blotting for hCD31 and hvWF, as previously described [16]. All lanes in the hCD31 blot were from the same X-ray film. b-actin levels
were measured on the same samples and served as a loading control. (D) qRT-PCR was used to assess mRNA expression for the EC markers
ESAM, CD31, and VWF in late passage TDECs relative to early passage TDECs. Values shown represent the average of at least triplicate reactions
and p values were from a standard Student’s t test.
doi:10.1371/journal.pone.0037138.g002
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were plated in Matrigel as previously described [16] and incubated under standard normoxic conditions for six days. Typical light microscopic fields
are shown. All photos are shown at identical magnifications with the black bar representing 100 mm. (B) The experiment from A was repeated except
that cultures were incubated for six days under moderately hypoxic conditions (1% O2) followed by an additional four day recovery period under
normoxic conditions. (C) The total number of tubes from B as well as those from parallel plates of cells cultured 10 d in normoxia (control) were
quantified. The plot depicts the mean values (6SEM) from three independent experiments. The p value was determined for only the late TDECs using
a one-tailed Student’s t test. (D) GFP-tagged H460 tumor cells or early or late TDECs (1,000 cells) incubated alone or mixed with non-GFP-tagged
HUVECs (10,000 cells). The cells were then cultured for two days under normoxic conditions in a standard Matrigel-based tube assay. Brightfield and
UV fluorescence photographs were taken and the merged images shown. In the first two cases, the white arrows indicate GFP+ tumor cells or early-
passage TDECs that lie adjacent to but have not incorporated into small groups of HUVECs. Arrows in the bottom two panels indicate late passage
TDECs that have incorporated into HUVEC tubes. Note that when GFP-tagged H460 tumor cells and early and late GFP+ TDECs were plated without
HUVECs, they remained rounded after 2 days of culture on Matrigel (see Figure S1). All photos are shown at identical magnifications with the black
bar representing 100 mm. Enlargements of representative views (areas in white rectangles) are also shown. Original images in panels A, B, and D were
taken at 106magnification.
doi:10.1371/journal.pone.0037138.g003
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parental H460 cells. To investigate this, we performed quantitative
real-time polymerase chain reaction (qRT-PCR) on 16 of these
transcripts(primersetsarelistedinTableS1).RelativetoH460cells,
whose expression levels for all transcripts were arbitrarily set at one,
we found changes of .1.5-fold in 7 transcripts from early TDECs
(LSAMP, DEPDC1B, ODZ2, FAM155A, EFNB2, LIG4, and
MACROD2) and 6 transcripts from late TDECs (LRP1B, LSAMP,
NLGN1,RAB3C,FAM155A,andMACROD2)(FigureS8).Relativeto
early-passage TDECs, late-passage TDECs showed statistically
significant altered expression with 5 of 16 transcripts, namely those
of LRP1B, RAB3C, FAM155A, EFNB2, and MACROD2 (Figure S8).
The nature of these changes was complex and could not always be
predictedbythetypeofalterationoftherespectivegenomicloci.The
most dramatic example was seen in the case of LRP1B transcript
expression, which was increased 16-fold in late-passage TDECs,
despite being associated with a hemizygous allelic loss (Table 1 and
Figures S2Band S8).
Figure 4. Tumor xenograft blood vessel density and size increase with continued serial passage of TDECs. Tumor xenografts were
established from inoculating a mix of non-GFP-tagged H460 cells (95%) and early- or late-passage TDECs (5%) into nude mice. Control tumor
xenografts were similarly derived from inoculating non-GFP-tagged H460 cells and 5% GFP+ H460 cells. Paraffin-embedded sections were then
prepared from the xenografts and stained with hematoxylin and eosin (A) so that tumor blood vessels could be easily identified. Typical examples of
blood vessels from each xenograft type are indicated by arrows. The total number of tumor blood vessels (B), as well as the number of vessels that
were small (#25 mm), medium (25–100 mm), and large ($100 mm) as measured by their longest dimension (C), were quantified from between 19 and
25 individual fields for each tumor type. The graphs represent the mean number of vessels per field (6SEM) and the statistical analysis was performed
using a two-tailed Student’s t test (*, p,0.05; **, p,0.001; ***, p,0.0001).
doi:10.1371/journal.pone.0037138.g004
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Although the tumor vasculature has been classically viewed as
arising from extra-tumoral sources, numerous studies have
demonstrated that some of the cells comprising tumor blood
vessels or its stroma display evidence of GI [39–45]. Our recent
finding that tumor cells can directly transdifferentiate into ECs in
vivo, and that they stably retain this phenotype, provides one
potential explanation for these findings as does the observation
that some tumor cells may acquire EC-like properties under
particular in vitro conditions [16,46]. These findings are supported
by recent observations that a substantial proportion of TAECs
from primary human glioblastomas appear to be of tumor cell or
tumor stem cell origin [17,18]. Taken together, these observations
suggest that tumor cells may engage in EMT, a potentially
intermediate stage in TDEC differentiation. During the EMT,
tumor cells lose junctional attachments, become more spindle-like,
and acquire more invasive and migratory behaviors [47–49]. The
tumor cell derivation of TDECs thus provides reason to suspect
that they may share the attribute of GI. The combination of
functional plasticity and GI could provide the means for TDECs
to adapt to microenvironmental challenges imposed by the
growing tumor and to evade anti-angiogenic therapies despite
being initially sensitive [17].
Based upon previously published [16] as well as our current
work, H460 tumor cells and early-passage TDECs are polyclonal
populations with essentially no identifiable differences based on
karyotypes or SNP profiling. In contrast, late passage TDECs
comprise a monoclonal or oligoclonal population with an
enhanced revascularization potential. This advantage is only seen
upon serial in vivo passage as we have found that comparable
periods of in vitro propagation neither increases the growth rate of
early passage TDECs nor allows for clonal populations to emerge
(unpublished data) These findings provide further evidence that
the in vivo micro-environment plays a key role in selecting for
TDEC populations that are optimized for participating in tumor
neovasculature development.
Late-passage, serially-passaged TDECs possess a limited num-
ber of well-defined chromosomal gains and deletions. That the
majority of these alterations affect genes that have been implicated
in EMT, vasculogenesis, or tumor suppression provides support to
a model for which one or more of these genes play a role(s) in the
TDEC developmental program. Future studies will be needed to
Figure 5. Analysis of SNP array profiles for four representative genomic alterations. Shown are genomic alterations found in late passage
TDECs on chromosomes 2, 3, and 5. In each case, the results shown (either Log R Ratio or B Allele Frequency) represent those that most clearly depict
the chromosomal alteration, although both types of analyses were used for interpretations. SNP array profiles for all genomic alterations detected are
shown in Figures S2, S3, S4, S5, S6, and S7. Chromosomal gains (green) and deletions (red) in late-passage TDECs relative to early passage TDECs are
indicated as well as the base positions of the alterations on the chromosomes. The expanded regions below the SNP array plots show the genes
within and adjacent to the sites of chromosomal alteration. The boundaries of the chromosomal alterations were determined using GenomeStudio
software (version v2009.2) to identify SNP coordinates and the Ensembl Genome Browser 57 database.
doi:10.1371/journal.pone.0037138.g005
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differentiation process.
In addition to the vascular and tumorigenic roles mentioned
above, several of the genes affected by TDEC gains/deletions are
also active in neurogenesis (see Table 1). This may relate to the
tendency of blood vessels and nerves to develop coordinately along
similar anatomic pathways and to the fact that nerve-derived
signals may also influence vascular patterning [50–53]. Moreover,
certain highly motile and invasive TDECs, which might be
expected to possess a functional advantage for the type of tumor
repopulating activity seen in tumor xenografts, have properties
that are highly reminiscent of the cells comprising axonal growth
cones [50–54]. The precise role of these genes in TDEC formation
and function and their relationship to the EC and neuronal
developmental process remain to be determined.
Although the EC-like properties and behaviors of TDECs
clearly increase with in vivo passage number (Figures 2 and 3), the
cells remain morphologically distinguishable from primary ECs
such as HUVECs (Figure 3A and B). The less than complete EC-
like appearance of TDECs may reflect the different pathways that
drive differentiation of these cells compared to true ECs. Certain
key elements of the normal EC differentiation program that are
lost or rendered dysfunctional as a consequence of the transfor-
mation process and/or the ensuing GI may play independent roles
as well. Despite these less than complete phenotypes, the fact that
late-passage TDECs are capable of better vascularizing tumor
xenografts (Fig. 4) attests to their increasing ability to function
within an in vivo context.
Together with previous observations [16], the approaches
described here should allow a number of interesting questions
pertaining to TDEC development and adaptive selection to be
addressed. Among these is whether TDECs of diverse tumor types
share similar regions of gains/deletions and whether, within these
regions, the genes most responsible for TDEC evolution can be
better defined with respect to function. The short time-frame over
which TDEC evolution occurs should also allow investigation into
whether the development of clinical refractoriness to anti-
angiogenesis therapies is associated with the emergence of TDEC
clonal subsets related to but distinct from those described here.
Materials and Methods
Ethics
All mouse studies were conducted according to Animal Welfare
Act and the Public Health Service Policy and approved by the
Table 1. Summary of genomic alterations in late passage H460 TDECs.
Chromosomal Position &
Alteration Gain/Del
Possible Genes
Affected
GenBank
Accession
Number
Location of
Alteration
Relative to
Altered Gene Proposed Biological Role(s) Refs.
2p16.3 (50,190,353-50,381,744) Gain NRXN1 AB011150 Exons 20-22 nervous and vascular systems 23
2q22.1 (142,210,528-142,468,442) Del LRP1B NM_018557 Exon 3 deleted in cancers 24
3q13.31/32 (117,059,636-117,473,977) Del LSAMP NM_002338 59 tumor suppressor, VEGFR1 regulator 25
LSAMP-AS3 59 noncoding LSAMP antisense RNA 25
LSAMP-AS4 59 noncoding LSAMP antisense RNA 25
3q26.31 (173,271,684-173,472,327) Del NLGN1 NM_014932 Exons 1b-2 nervous and vascular systems 23
4q34.3 (182,009,132-182,158,533) Del LINC00290 Intergenic
5q11.2 (58,349,882-58,730,285) Del PDE4D NM_001104631 Exons 2–5 promotes survival, proliferation, EMT 26
RAB3C NM_138453 39 exocytosis regulation 27
PART1 NR_024617 59 (long non-coding RNA)
DEPDC1B NM_018369 59 deleted in sporadic breast cancer 28
ELOVL7 NM_024930 59 LCFA elongase, prostate cancer 29
ERCC8 NM_000082 59 DNA repair 30
5q34 (164,826,163-165,260,961) Del ODZ2 AB032953 59 a transmembrane protein predominantly
expressed in nervous system; deregulated
in lymphoma
31,32
9p21.1 (28,378,229-28,587,832) Del LINGO2 AL353746 Exon 2 transmembrane protein, typically
expressed early in development
33
13q33.3 (107,685,848-107,885,801) Gain FAM155A L10374 Exons 2–3 unknown
ARGLU1 BC071587 39 required for estrogen-dependentgene
transcription and breast cancer cell growth
34
EFNB2 NM_004093 39 angiogenesis 35
LIG4 NM_002312 59 DNA repair 36
14q (entire chromosome) Loss All - -
20p12.1 (14,858,910-14,914,578) Del MACROD2 NM_080676 Intron 5 An O-acetyl-ADP-ribose deacetylase;
deleted in colorectal cancer
37,38
The nucleotide coordinates of genomic alterations in SP5 and SP6 TDECs were determined by the first and last SNPs that differed from those of early passage TDECs and
the precise locations were obtained using the Ensembl Genome Browser 57 database.
doi:10.1371/journal.pone.0037138.t001
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Committee (IACUC) (Permit Number: 0812276). The animals
were housed in pathogen-free units at Children’s Hospital of
Pittsburgh Rangos Research Building in compliance with IACUC
regulations. Age and gender matched Nu/Nu mice were
purchased from Harlan Sprague-Dawley Laboratories (Indianap-
olis, IN). For all surgical procedures, all efforts were made to
minimize suffering to the mice. The University of Pittsburgh
Institutional Review Board specifically approved this study.
Tumor Xenograft Growth, Cell Culture and Serial Passage
of TDECs
NCI-H460 human lung carcinoma (H460) cells were obtained
from the American Type Culture Collection (Manassas, VA) and
were cultured as previously described [16]. Authentication of
H460 cells, as well as the serially-passaged H460-derived TDECs,
was obtained by comparing the results obtained from the whole
genome SNP array analysis with previously published results
obtained by SKY analysis for NCI-H460 cells (see legend to
Figures S2, S3, S4, S5, S6, and S7). Human umbilical vein
endothelial cells (HUVECs) and EGM-2 EC-specific growth
medium were purchased from Cambrex Bio Science (Walkerville,
MD). Lentiviral packaging and infections to produce GFP-tagged
and G418-resistant H460 cells were performed as previously
described [16]. Initially, tumor xenografts were propagated by
inoculating tagged H460 cells (10
6) subcutaneously into the flanks
of nude mice. The tumors were allowed to grow to the maximal
allowable diameter of ca. 2 cm (typically 4–6 wks) and were then
excised, minced, collagenase-digested, and passed successively
through 100 mm and 40 mm mesh filters to obtain single cell
suspensions (BD Falcon Cell Strainer, BD Biosciences, Franklin
Lakes, NJ). Total murine and human tumor-associated endothelial
cells (TAECs) were isolated from the bulk tumor cell population
using two rounds of selection with magnetic beads coupled to
human- and murine-specific anti-CD31 monoclonal antibodies
(mAbs) [16]. The following day, cultures were examined using
brightfield and ultraviolet microscopy to determine the percentage
of GFP+ ECs (i.e. TDECs) and then subsequently selected for at
least 7 days in G418-containing medium (500 mg/ml). The
resulting human-derived cell population was termed ‘‘serial
passage 0 (SP0) TDECs’’ and was routinely maintained in
EGM-2 medium [16]. Serial passage was performed by re-
inoculating 50,000 SP0 TDECs with 950,000 untagged H460
tumor cells (a 1:20 ratio) into nude mice. Subsequently arising
tumors were then used for repeat rounds of TDEC isolation and
the generation of additional serially-passaged TDECs up to SP7.
‘‘Early passage’’ TDECs were generally comprised of SP1 cells
and occasionally of SP0 cells, whereas ‘‘late passage’’ TDECs were
comprised of SP6 or SP7 cells and occasionally of SP5 cells.
Separate fragments of tumors were used for the preparation of
frozen and paraffin-embedded sections.
Evaluation of EC-specific Markers and Functions
Following their expansion, those TDECs not being used for
serial passage studies in vivo were used to assess EC marker
expression. For flow cytometry, at least 10,000 cells from short-
term cultures of in vitro-selected TDECs were stained with anti-
human CD31 and analyzed with a FACSCalibur flow cytometer
(BD Biosciences). Data were analyzed and processed using BD
FACSDiva software. For procedures requiring fixation, TDECs
were grown on glass coverslips, fixed in PBS-4% paraformalde-
hyde and stained with antibodies against either human vWF or
human ESAM as previously described [16]. We also quantified the
uptake of rhodamine-tagged Ulex europeus lectin (E-lectin: Vector
Laboratories, Burlingame, CA) and AlexaFluor 594-tagged
acetylated low-density lipoprotein (AcLDL) (Invitrogen Molecular
Probes) as previously described [16]. All photographs for
fluorescence microscopy were taken with an Olympus Fluoview
1000 confocal microscope at a magnification of 40X–60X, except
rhodamine-labeled E-lectin staining which was photographed at
20X. Adobe Photoshop CS2 (version 9.0, Adobe Systems, San
Jose, CA) was employed for image analysis. qRT-PCR analysis of
EC markers was performed as previously described [16].
Tube Formation Assay
Characterization of tube formation in Matrigel was performed
at 37uC as previously described [16] under normoxic or hypoxic
conditions using a Hypoxic Glove Box incubator (Coy Laboratory
Products Inc., Grass Lake, MI). Wells from 24-well plates were
initially coated with Cultrex BME Growth Factor Reduced
PathClear matrix (R&D Systems, Minneapolis, MN) (100 ml).
TDECs, the original tumor cells (1000 cells/well) and HUVECs
(10,000 cells/well) were then seeded in EGM-2 medium for the
times and under the conditions indicated in the figures. Tube
formation was typically assessed at 2, 6, and 10 d, at which points
tubes were quantified and photographed using a Zeiss Axiovert
135 inverted microscope equipped with a Sony DXC-970MD
3CCD Color Video Camera. In assessing and quantifying TDEC
tube formation, a ‘‘tube’’ was arbitrarily defined as the formation
of an enclosed space surrounded by at least 10 cells linked end-to-
end with a 1–2 cell layer thickness for at least 75% of the circle.
Evaluation of Tumor Blood Vessels
Hematoxylin and eosin staining of paraffin-embedded sections
from tumor xenografts was performed by the University of
Pittsburgh Histology Core Laboratory. Criteria for tumor blood
vessel identification were the presence of an identifiable lumen
containing red blood cells.
Whole Genome SNP Array, Chromosome Analysis, and
qRT-PCR
SNP analyses were performed at The University of Pittsburgh
Genomics and Proteomics Core Facility with using Ilumina 1 M
DNA Analysis Bead Chips, which contains approximately 10
6
SNPs with a mean genome spacing of 2.7 kb (median 1.7 kb).
Analysis of the raw data was carried out using GenomeStudio
software (version v2009.2). Changes in Log R Ratio and B Allele
Frequency were used to identify gains or deletions within
individual chromosomes. The software also allowed for identifi-
cation of genes within the immediate proximity of duplicated or
deleted genomic loci. The boundaries of the chromosomal
alterations were determined using the identified SNP coordinates
with the Ensembl Genome Browser 57 database. For qRT-PCR
analysis of transcripts of genes identified by whole genome SNP
array, total RNA was first purified using RNeasy mini-columns
(Qiagen, Inc., Valencia, CA) (16) and 50 ng of input RNA was
used in a SYBR Green-based assay (Quantitect, Qiagen)
according to the directions of the supplier. Primers used to assess
transcript levels of genes putatively affected by genomic alterations
in late passage TDECs were selected from the MGH/Harvard
PrimerBank site (http://pga.mgh.harvard.edu/primerbank) or
were self-designed, with the exception of those for NLGN1 [55].
These latter primers are described in Table S1 and were
synthesized by International DNA Technologies (Coralville, IA).
Confirmation of the predicted PCR product sizes was achieved by
agarose gel electrophoresis and is shown in Figure S9. Data
analysis was performed on an Applied Biosystems 7300 instrument
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data was carried out using a comparative CT method and GAPDH
was used as an endogenous control. Fold differences in the SP1
and SP7 mRNA levels relative to H460 RNA were then calculated
by 2
2[DCT(SP1/7)2 DCT(H460)].
Statistical Analysis
Data were analyzed using either the one-tailed or two-tailed
Student’s t test as appropriate.
Supporting Information
Figure S1 H460 tumor cells and early and late TDECs
remain rounded after 2 d on Matrigel in normoxia.
(TIF)
Figure S2 SNP array profile analyses demonstrating
genomic alterations for chromosome 2. All other genomic
alterations observed for late-passage TDECs are shown in
Supplemental Figures S3–S7. In each case, the results shown
(either Log R Ratio or B Allele Frequency) represent those that
most clearly depict the chromosomal alteration, although both
types of analyses were used for interpretations. It is noteworthy
that for all chromosomes of H460-derived TDEC cell lines, a good
agreement was found between the overall copy number based on
B-allele frequency and log R ratio parameters and the number of
chromosomes detected by SKY analysis in the H460 cell line
previously reported [Liu et al. (2004) Modeling of lung cancer by
an orthotopically growing H460SM variant cell line reveals novel
candidate genes for systemic metastasis. Oncogene 23:6316-6324].
Chromosomal gains (green) and deletions (red) in late-passage
TDECs relative to early passage TDECs are indicated as well as
the base positions of the alterations on the chromosomes. The
expanded regions below the SNP array plots show the genes
within and adjacent to the sites of chromosomal alteration. The
boundaries of the chromosomal alterations were determined using
GenomeStudio software (version v2009.2) to identify SNP
coordinates and the Ensembl Genome Browser 57 database.
(TIF)
Figure S3 SNP array profile analyses demonstrating
genomic alterations for chromosome 3. A more detailed
description of the SNP array analysis is given in the legend to
Supplementary Figure S2.
(TIF)
Figure S4 SNP array profile analyses demonstrating
genomic alterations for chromosomes 4 and 5. A more
detailed description of the SNP array analysis is given in the legend
to Supplementary Figure S2.
(TIF)
Figure S5 SNP array profile analyses demonstrating
genomic alterations for chromosomes 5 and 9. A more
detailed description of the SNP array analysis is given in
the legend to Supplementary Figure S2.
(TIF)
Figure S6 SNP array profile analyses demonstrating
genomic alterations for chromosomes 13 and 14. A more
detailed description of the SNP array analysis is given in the legend
to Supplementary Figure S2.
(TIF)
Figure S7 SNP array profile analyses demonstrating
genomic alterations for chromosome 20. A more detailed
description of the SNP array analysis is given in the legend to
Supplementary Figure S2.
(TIF)
Figure S8 qRT-PCR analysis of genes within or nearby
chromosomal alterations detected in late passage
TDECs by SNP analysis. The relative amount of transcripts
was quantified by a comparative CT method with GAPDH used as
an endogenous control and the DCT values calculated for each
sample. Results depicted in the graph represent mean values
obtained (6SEM) from 3 independent sets of biological samples
(i.e., 3 independent RNA preparations each of H460, SP1, and
SP7 TDECs), except for NRXN1, RAB3C, and ERCC8, which
represent results from two independent sets of RNA samples.
*, p,0.05; **, p,0.01.
(TIF)
Figure S9 Evaluation of qRT-PCR products following
amplification from H460 RNA. Products were electropho-
resed on a 4% NuSieve agarose gel (Cambrex Bio Science
Rockland, Inc., Rockland, ME).
(TIF)
Table S1 qRT-PCR primers used in the analysis of Fig.
S8.
(TIF)
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